Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 2Sarcoma 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 3Gastrointestinal Neoplasms 2Stomach Neoplasms 1Rectal Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Kidney Neoplasms 1Colonic Neoplasms 1Carcinoma 1Advanced Hepatocellular Carcinoma 1

Interventions

Gemcitabine 11pembrolizumab 10Oxaliplatin 7Nivolumab 7Irinotecan 7Fluorouracil 7Capecitabine 7durvalumab 6Sorafenib 6Leucovorin 6Cyclophosphamide 6Paclitaxel 5Ipilimumab 5tislelizumab 3poly ICLC 3lenvatinib 3fludarabine 3Sunitinib 3Radiotherapy 3Cisplatin 3Cetuximab 3130-nm albumin-bound paclitaxel 3seocalcitol 2selinexor 2pemigatinib 2futuximab 2fludarabine phosphate 2donafenib 2cemiplimab 2atezolizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma × trebananib × Gastrointestinal × Clear all
NCT00752570 2015-09-02

A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinoma

Amgen

Phase 2 Completed
144 enrolled
Gastrointestinal

Carcinoma, Colonic Neoplasms, Gastrointestinal Neoplasms, Neoplasm Metastasis, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡